Persistence of a proinflammatory status after treatment of the acute myocardial infarction

Abstract

AimTo evaluate the lipid‐lowering and antiplatelet combined strategies on the expression of the receptors CCR2, CCR5, and CX3CR1 and the percentage of CCR2, CCR5, and CX3CR1 cells in monocyte subtypes after acute myocardial infarction.MethodsProspective, randomized, open‐label study, with blinded analyses of endpoints (PROBE, ClinicalTrials.gov Identifier: NCT02428374, registration date: April 28, 2015). Participants were treated with rosuvastatin 20 mg or simvastatin 40 mg plus ezetimibe 10 mg, as well as ticagrelor 90 mg or clopidogrel 75 mg. The chemokine receptors CCR2, CCR5, and CX3CR1 were analyzed by real‐time polymerase chain reaction as well as the percentages of CCR2, CCR5, and CX3CR1 cells in the monocyte subtypes (classical, intermediate, and non‐classical), which were quantified by flow cytometry, at baseline, and after 1 and 6 months of treatment.ResultsAfter comparisons between the three visits, regardless of the treatment arm, there was an increase in CCR2 expression after treatment, as well as an increase in intermediate monocytes CCR2+ and a reduction in non‐classical monocytes CCR2+ at the end of treatment. There was also a lower expression of CCR5 after treatment and an increase in classical and non‐classical monocytes CCR5+. Concerning CX3CR1, there were no differences in the expression after treatment; however, there were reductions in the percentage of intermediate and non‐classical monocytes CX3CR1+ at the end of treatment.ConclusionsThe results suggest the persistence of the inflammatory phenotype, known as trained immunity, even with the highly‐effective lipid‐lowering and antiplatelet therapies. Geriatr Gerontol Int 2023; 23: 700–707.